Skip to main content

Table 2 Plasma lipid/lipoprotein profile of Alzheimer’s disease patients and control subjects

From: Plasma and cerebrospinal fluid cholesterol esterification is hampered in Alzheimer’s disease

 

AD

(n = 70)

CN

(n = 74)

P

Total cholesterol (mg/dL)

193.7 ± 44.3

198.4 ± 39.7

0.64

Unesterified cholesterol (mg/dL)

44.0 ± 15.7

56.0 ± 9.8

 < 0.0001

Unesterified/total cholesterol

0.23 ± 0.08

0.28 ± 0.03

0.0002

Cholesteryl esters (mg/dL)

251.3 ± 70.1

244.9 ± 54.4

0.66

LDL cholesterol (mg/dL)

117.9 ± 38.6

106.9 ± 32.1

0.06

HDL cholesterol (mg/dL)

54.0 ± 16.1

57.1 ± 12.1

0.11

Non-HDL cholesterol (mg/dL)

139.7 ± 40.9

137.9 ± 36.3

0.78

Triglycerides (mg/dL)

105.0 (82; 129)

106.5 (75; 123)

0.95

Phospholipids (mg/dL)

209.2 ± 39.8

212.3 ± 42.1

0.94

Apolipoprotein A-I (mg/dL)

143.2 ± 27.8

138.8 ± 20.9

0.29

Apolipoprotein A-II (mg/dL)

28.6 ± 4.7

29.1 ± 7.3

0.83

Apolipoprotein E (mg/dL)

3.4 ± 1.1

2.9 ± 0.8

0.37

Apolipoprotein B (mg/dL)

96.7 ± 24

110.9 ± 31.4

0.03

LCAT activity (nmol/mL/h)

29.4 ± 12.4

36.4 ± 7.8

 < 0.0001

CER (nmol/mL/h)

30.2 ± 12.9

35.9 ± 12.0

0.02

Preβ-HDL (% of total apoA-I)

9.95 ± 6.40

13.63 ± 4.12

0.03

Aqueous diffusion CEC (%)

6.7 ± 1.1

5.3 ± 1.0

 < 0.0001

ABCG1 CEC (%)

4.8 ± 0.8

5.7 ± 1.5

0.0004

ABCA1 CEC (%)

3.7 ± 0.8

4.4 ± 1

0.001

  1. AD Alzheimer’s disease, CN cognitive normal controls, LCAT lecithin:cholesterol acyltransferase, CER cholesterol esterification rate, CEC, cholesterol efflux capacity, ABCG1 ATP-binding cassette G1, ABCA1 ATP-binding cassette A1
  2. Data are reported as mean ± SD or median (1st; 3rd quartile). AD and controls were compared by the Wilcoxon rank-sum test